Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 1999

View Archived Issues

Genzyme explores cell therapy for cardiovascular disease

Epitope announces OraQuick agreement with Organon Teknika

Slow-release naltrexone enters the clinic

BioStratum receives patent on antiangiogenic agent

Cypros given notice of allowance on U.S. patent for NCCBs

TMR plus CABG offers positive clinical results

NeXstar: Q1 1999 highlights

Lilly: Q1 1999 highlights

Company Profile: Discovery Laboratories

IGT Pharma initiates phase I testing of antitumor drug

Licensing opportunity from NIH: lavendustin A analogues with antiproliferative activity

Continuing focus on PARP inhibitors at Guilford

Potent, optically pure analogues of camptothecin designed at SCRAS

New CRF antagonists described by DuPont for stress-related disorders

FDA advisory committee does not favor approval of temozolomide for melanoma indication

Sibia identifies novel mGluR5-selective compounds

Purified flaxseed lignan has significant beneficial effects in hypercholesterolemic atherosclerosis

Highly functionalized analogues of ingenol prepared in the search for PKC activators

Triazine-based adenosine antagonists in development at Boehringer Ingelheim

HMR describes new NCBE inhibitor series for cardiovascular disorders

Pyrazoles acting as modulators of cGMP production disclosed by Hoechst Marion Roussel

Merck's Maxalt proves effective in women with menstrual migraine

Open-label trial demonstrates efficacy of gabapentin monotherapy in AIDS-related neuropathy

Aggrenox unanimously recommended for approval for stroke indication

Definitive copromotion agreement for cilostazol signed by Otsuka and Pharmacia & Upjohn

NeuroBloc proves effective and safe in two pivotal trials in cervical dystonia

Botox in migraine, poststroke spasticity: results presented at AAN meeting

Company Profile: Eligix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...